Trial Profile

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plozasiran (Primary)
Indications Dyslipidaemias
Focus Adverse reactions
Sponsors Arrowhead Pharmaceuticals

Most Recent Events

18 Nov 2024 Results assessing long term safety and efficacy of plozasiran in subjects with elevated TGs presented at the American Heart Association Scientific Sessions 2024
23 Oct 2023 Status changed from recruiting to active, no longer recruiting.
13 Sep 2022 New source identified and integrated (European Clinical Trials Database: EudraCT2022-001135-85).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com